pre-IPO PHARMA

COMPANY OVERVIEW

AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. To do this, we first work to understand the areas of unmet need and the experience of living with any disease we are targeting. We then use our extensive experience in drug development to identify and advance therapies that can significantly improve clinical outcomes while offering the strongest opportunities for approval.


LOCATION

  • London, , UK
  • Durham, NC, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders
  • Rare Diseases

  • WEBSITE

    https://www.amo-pharma.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    woodford-investment-management


    PRESS RELEASES


    Sep 19, 2023

    AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy USA - English USA - English


    Sep 6, 2023

    AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy USA - English USA - English


    Apr 25, 2023

    AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy USA - English USA - English


    Feb 27, 2023

    AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy


    Feb 27, 2023

    AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy USA


    For More Press Releases


    Google Analytics Alternative